** Drug developer's shares MTEM.O up 9% at $2.95 after
market
** Company reports Q4 loss of 18 cents/shr vs loss of 57
cents/shr a year earlier; analysts had expected a Q4 loss of 40
cents/shr - Refinitiv data urn:newsml:reuters.com:*:nASA035OZ
** Quarterly revenue rose more than 5x to $18 mln
urn:newsml:reuters.com:*:nGNX2d0D7X
** All 8 brokerages covering MTEM rate the stock "buy" or
higher; median PT $11.50
** Up to Monday's close, stock down 31% YTD
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7))